Future considerations for the mRNA-lipid nanoparticle vaccine platform

Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccines against coronavirus disease in 2019 (COVID-19). However, there are many questions rega...

Descripción completa

Detalles Bibliográficos
Autores principales: Igyártó, Botond Z, Jacobsen, Sonya, Ndeupen, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065267/
https://www.ncbi.nlm.nih.gov/pubmed/33906124
http://dx.doi.org/10.1016/j.coviro.2021.03.008
_version_ 1783682303588827136
author Igyártó, Botond Z
Jacobsen, Sonya
Ndeupen, Sonia
author_facet Igyártó, Botond Z
Jacobsen, Sonya
Ndeupen, Sonia
author_sort Igyártó, Botond Z
collection PubMed
description Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccines against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology.
format Online
Article
Text
id pubmed-8065267
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-80652672021-04-26 Future considerations for the mRNA-lipid nanoparticle vaccine platform Igyártó, Botond Z Jacobsen, Sonya Ndeupen, Sonia Curr Opin Virol Article Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccines against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology. Elsevier B.V. 2021-06 2021-04-24 /pmc/articles/PMC8065267/ /pubmed/33906124 http://dx.doi.org/10.1016/j.coviro.2021.03.008 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Igyártó, Botond Z
Jacobsen, Sonya
Ndeupen, Sonia
Future considerations for the mRNA-lipid nanoparticle vaccine platform
title Future considerations for the mRNA-lipid nanoparticle vaccine platform
title_full Future considerations for the mRNA-lipid nanoparticle vaccine platform
title_fullStr Future considerations for the mRNA-lipid nanoparticle vaccine platform
title_full_unstemmed Future considerations for the mRNA-lipid nanoparticle vaccine platform
title_short Future considerations for the mRNA-lipid nanoparticle vaccine platform
title_sort future considerations for the mrna-lipid nanoparticle vaccine platform
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065267/
https://www.ncbi.nlm.nih.gov/pubmed/33906124
http://dx.doi.org/10.1016/j.coviro.2021.03.008
work_keys_str_mv AT igyartobotondz futureconsiderationsforthemrnalipidnanoparticlevaccineplatform
AT jacobsensonya futureconsiderationsforthemrnalipidnanoparticlevaccineplatform
AT ndeupensonia futureconsiderationsforthemrnalipidnanoparticlevaccineplatform

Ejemplares similares